Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients
Authors:
- 9 May 2015
- journal article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 34 (12) , 2119-2126
Abstract
Despite systemic glucocorticoids are widely used, risk factors for most of their adverse events and patients’ beliefs about the drug are poorly known. An online survey was conducted between February and July 2013 through the website www.cortisone-info.fr. Demographic (e.g., age, gender) and therapeutic (e.g., type of prescribed glucocorticoid, duration of prescription) data were collected. Patients were further asked to answer questions about glucocorticoid-induced adverse events and their beliefs about efficacy and safety of the drug. Risk factors for adverse events and efficacy/safety beliefs were assessed using multivariate logistic regression models. Eight hundred twenty questionnaires were analyzed (women 74.3 %; median age 49 [34–62] years, median equivalent prednisone dosage 20 [10–48] mg/day). The most frequently reported adverse events were insomnia (n = 477, 58.2 %), mood disturbances (n = 411, 50.1 %), hyperphagia (n = 402, 49.0 %), and lipodystrophy (n = 387, 47.2 %). The risk of some adverse events (e.g., weight gain, easy bruising) increased with the duration of exposure while other adverse events (e.g., insomnia, mood disorders, epigastric pain) were present since the first days of exposure. The risk of hirsutism, altered wound healing, mood disturbances, weight gain, lipodystrophy, hyperphagia, and epigastric pain decreased with age. Cutaneous disorders, morphological changes, and epigastric pain were more frequently reported by women. Interestingly, patients prescribed prednisolone reported less adverse events than those prescribed prednisone. No adverse event, demographical or prescribing characteristics were associated with beliefs about efficacy while factors associated with safety concerns were age (OR: 1.2 [1.1–1.3] per 10-year increase), osteoporosis (OR: 3.3 [1.4–7.9]), easy bruising (OR: 1.6 [1.1–2.3]), insomnia (OR: 1.7 [1.2–2.4]), and weight gain (OR: 1.6 [1.1–2.2]). These results may help clinicians to adapt information speech, therapeutic education, and clinical and laboratory monitoring of patients prescribed glucocorticoid therapy.Keywords
This publication has 17 references indexed in Scilit:
- Long-term systemic glucocorticoid therapy: Patients’ representations, prescribers’ perceptions, and treatment adherenceJoint Bone Spine, 2014
- Prevalence of oral glucocorticoid usage in the United States: A general population perspectiveArthritis Care & Research, 2012
- Suicidal Behavior and Severe Neuropsychiatric Disorders Following Glucocorticoid Therapy in Primary CareAmerican Journal of Psychiatry, 2012
- Pharmacologie des glucocorticoïdesLa Presse Médicale, 2012
- Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature ReviewClinical Therapeutics, 2011
- Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 yearsRheumatology, 2011
- Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases, 2010
- Dose-related patterns of glucocorticoid-induced side effectsAnnals of the Rheumatic Diseases, 2009
- Incidence and risk factors for corticosteroid-induced lipodystrophy: A prospective studyJournal of the American Academy of Dermatology, 2007
- Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinionBritish Journal of Dermatology, 2007